Affordable Access

deepdyve-link
Publisher Website

The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?

Authors
  • Lemke, Emily1
  • Sahasrabudhe, Deepak2
  • Guancial, Elizabeth3
  • Bylow, Kathryn4
  • Johnson, Scott5
  • Messing, Edward2
  • Kilari, Deepak4
  • 1 Department of Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: [email protected]
  • 2 Department of Medicine, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY.
  • 3 Florida Cancer Specialists, Sarasota, FL.
  • 4 Department of Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI.
  • 5 Department of Urology, Medical College of Wisconsin, Milwaukee, WI.
Type
Published Article
Journal
Clinical Genitourinary Cancer
Publisher
Elsevier
Publication Date
Aug 01, 2020
Volume
18
Issue
4
Identifiers
DOI: 10.1016/j.clgc.2020.01.003
PMID: 32085986
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC). Responses to first-line platinum-based therapy tend to be short-lived with potential toxicity. Despite the approval of checkpoint inhibitors, the long-term prognosis for patients with metastatic UC remains dismal. Herein we report the case of a patient with a solitary pulmonary metastatic lesion of urothelial origin as the only site of metastatic disease who remained free of disease for more than 2 years without systemic therapy after metastasectomy. We review the literature discussing the role of combined surgical and medical management of oligometastatic UC. As our case illustrates, a growing body of evidence suggests a potential role for a multimodal approach in patients with oligometastatic UC. Copyright © 2020 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times